<DOC>
	<DOCNO>NCT00216112</DOCNO>
	<brief_summary>Imatinib mesylate inhibitor receptor tyrosine kinases platelet-derived growth factor ( PDGF ) stem cell factor ( SCF ) , c-Kit , inhibits PDGF- SCF-mediated cellular event . Docetaxel promote cell growth arrest inhibit deassembly tubulin promote time microtubule assembly . Docetaxel single agent activity ovarian cancer response rate 30-40 % platinum refractory setting . The combination imatinib mesylate docetaxel potential synergistic effect , base previous report show synergy in-vitro in-vivo PDGFR inhibitor PI3K inhibitor taxane chemotherapy . This trial investigate efficacy combination imatinib mesylate docetaxel treat patient advanced , platinum-refractory ovarian cancer primary peritoneal carcinomatosis .</brief_summary>
	<brief_title>Imatinib Mesylate Combination With Docetaxel Advanced , Platinum-Refractory Ovarian Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Submit tumor serum sample central review - Imatinib 600 mg ( orally qd ) ; - Docetaxel 30mg/m2 ( 4 6 week ) ; 1 cycle = 6 week - Evaluate every cycle Each cycle begin granulocyte count &gt; 1,500/mm3 platelet count &gt; 100,000/mm3 treatment-related toxicity &lt; grade 1 . If toxicity resolve grade 0 1 three week , patient withdrawn study . For day 8 , 15 , 22 patient must absolute neutrophil count &gt; 1,000/mm3 great platelet count &gt; 75,000/mm3 . Imatinib mesylate administer platelet &gt; 20,000 ANC &gt; 500 . ECOG performance status 0 1 Hematopoietic : · - ANC &gt; 1,500/mm3· - Platelets &gt; 100,000 mm3· - Hgb &gt; 8g/dl Hepatic : · - Albumin &gt; 3gm/dL· - Total bilirubin &lt; ULN· - Maximum Alk Phos : &gt; 2.5x &lt; 5x ULN Renal : · - Creatinine &lt; 1.5 x ULN· ( Cockroft Gault ) Cardiovascular : · - No grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month prior begin protocol therapy ) Pulmonary : · - Not specify</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically document diagnosis ovarian cancer , primary peritoneal carcinomatosis fallopian tube cancer· Immunohistochemical documentation cKit PDGFR expression tumor At least one measurable site disease define RECIST evidence disease progression CA125 measurement Platinumrefractory platinumresistant No prior exposure imatinib ( Gleevec® ) single agent combination No chemotherapy within 28 day ( 42 day nitrosourea mitomycinC ) prior register protocol therapy . No prior radiotherapy ³ 25 % bone marrow No known brain metastasis . Negative pregnancy test No current breastfeed No investigational agent within 28 day prior protocol therapy No prior malignancy past 5 year unless primary malignancy currently clinically significant , require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ No severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) No know diagnosis human immunodeficiency virus ( HIV ) infection . No major surgery within 28 day prior register protocol therapy . No refractory ascites require drainage frequently month No presence clinically significant small bowel obstruction No prior exposure docetaxel ( exposure paclitaxel allow ) No parenteral nutrition within 28 day prior register protocol therapy . No concomitant treatment potent CYP 3A4 inhibitor ( i.e. , ketoconazole ) permit therapy protocol . No therapeutic anticoagulation warfarin study ( use low molecular weight heparin allow , necessary ) . No peripheral neuropathy &gt; grade 1 No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 . No serious concomitant systemic disorder incompatible study No prior malignancy exception curatively treat basal squamous carcinoma skin , carcinoma insitu cervix , cancer patient diseasefree &lt; 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>